EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Effects of tamoxifen on benign breast disease in women at high risk for breast cancer



Effects of tamoxifen on benign breast disease in women at high risk for breast cancer



Journal of the National Cancer Institute 95(4): 302-307



Background: In 1998 the National Surgical Adjuvant Breast and Bowel Project (NSABP) demonstrated that tamoxifen treatment reduced the incidence of both invasive and non-invasive breast cancer in women at high risk for the disease. We examined the effect of tamoxifen treatment on the incidence of benign breast disease and the number of breast biopsies in the same group of women. Methods: We examined the medical records of 13 203 women with follow-up who participated in the NSABP Breast Cancer Prevention Trial. Included in this analysis were women who had undergone a breast biopsy and who had histologic diagnoses of adenosis, cyst, duct ectasia, fibrocystic disease, fibroadenoma, fibrosis, hyperplasia, or metaplasia. The relative risk (RR) for each histologic diagnosis was estimated for women who received tamoxifen and for women who received placebo. We also tallied the number of biopsies that women in the placebo and tamoxifen groups underwent. Results: Overall, tamoxifen treatment reduced the risk of benign breast disease by 28% (RR=0.72, 95% confidence interval (CI)=0.65 to 0.79). Tamoxifen therapy resulted in statistically significant reductions in the risk of adenosis (RR=0.59, 95% CI=0.47 to 0.73), cyst (RR=0.66, 95% CI=0.58 to 0.75), duct ectasia (RR=0.72, 95% CI=0.53 to 0.97), fibrocystic disease (RR=0.67, 95% CI=0.58 to 0.77), hyperplasia (RR=0.60, 95% CI=0.50 to 0.71), and metaplasia (RR=0.51, 95% CI=0.41 to 0.62). Tamoxifen therapy also reduced the risk for fibroadenoma (RR=0.77, 95% CI=0.56 to 1.04) and fibrosis (RR=0.86, 95% CI=0.72 to 1.03). Compared with the placebo group, the tamoxifen group had 29% (95% CI=23% to 34%) fewer biopsies (1048 versus 1469) and 19% fewer women who underwent a biopsy (811 versus 1019). This resulted in a 29% reduction in the risk of biopsy in women treated with tamoxifen (RR=0.71, 95% CI=0.66 to 0.77). This risk reduction occurred predominantly in women younger than 50 years. Conclusion: Women in this study who received tamoxifen, especially younger women (i.e., <50 years), had a reduced incidence of clinically detected benign breast disease and underwent fewer breast biopsies.

(PDF emailed within 0-6 h: $19.90)

Accession: 010565192

Download citation: RISBibTeXText

PMID: 12591986

DOI: 10.1093/jnci/95.4.302



Related references

Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer. Journal of Clinical Oncology 33(28): 3137-3143, 2016

Risk of breast cancer from benign breast disease Incidence rates for breast cancer and intra observer reliability in classifying benign breast disease lesions. American Journal of Human Genetics 65(4): A330, 1999

Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump. Annals of Family Medicine 3(3): 242-247, 2005

Circulating breast tumour antigen-sensitive T lymphocytes in early breast cancer and high risk benign breast disease. British Journal of Surgery 66(12): 848-852, 1979

Tamoxifen for the reduction in the incidence of breast cancer in women at high risk for breast cancer. Annals of the New York Academy of Sciences 949: 345-348, 2002

Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B Trial. European Journal of Cancer 35(12): 1659-1666, 2000

Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer Co-operative Group DBCG 82B trial. European Journal of Cancer 35(12): 1659-1666, 1999

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. Journal of the National Cancer Institute 104(16): 1263-4; Author Reply 1266-8, 2012

The effect of tamoxifen on benign breast disease Findings from the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. Breast Cancer Research & Treatment 69(3): 210, October, 2001

Longitudinal analysis of benign breast disease in women developing breast cancer after a benign biopsy: A Mayo breast disease cohort study. Laboratory Investigation 88(Suppl. 1): 58A, 2008

Natural killer cell activity in women at high risk for breast cancer with and without benign breast syndrome. International Journal of Cancer 34(3): 303-308, 1984

Histopathologic risk factor for breast cancer in women with benign breast disease. Seminars in Surgical Oncology 4(4): 213-217, 1988